Plain-English translation of NCT06285890 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new medication called for adults with acute myeloid leukemia (a serious blood cancer) that has stopped responding to standard treatments. Researchers want to first understand whether this medication is safe, at what dose it works best, and whether it can help patients achieve remission or control their disease. Only a small group of patients will participate initially while doctors carefully monitor their health.
Patients whose leukemia comes back or doesn't respond to initial chemotherapy have very limited options, and outcomes are poor. This trial exists to test whether this medication could offer hope to people in that situation by targeting leukemia cells in a new way.
You likely qualify if…
You likely don't qualify if…
If enrolled, you would take the medication by mouth once daily on days 1 through 28 of each treatment cycle, taking it on an empty stomach (1 hour before or 2 hours after food). You would have regular clinic visits and blood tests to monitor how well the treatment is working and watch for any side effects. The study tracks how your disease responds, how long you survive, and how the medication behaves in your body.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
M.D. Anderson Cancer Center
Collaborators
HiberCell, Inc.
Enrollment target
~18 participants
Started
May 2024
Primary completion
December 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Abhishek Maiti, MD
M.D. Anderson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.